A Study of Q702 in Patients with Relapsed or Refractory Chronic Graft-versus-Host Disease

The primary objective of this study is to evaluate the efficacy of Q702 in subjects presenting with relapsed or refractory chronic graft-versus-host disease. This investigation is clinically relevant to determine the therapeutic potential of the investigational product in managing patients who have failed standard treatment regimens. No secondary objectives were specified in the provided data.

The study involves a total of 2 patients. The participant population consists of both males and females within the age range of 3 to 5 years. All subjects are diagnosed with chronic graft-versus-host disease, which is classified as a rare disease. The sponsor did not provide additional information regarding lifestyle considerations or specific selection processes.

This Phase 2 study utilizes a clinical trial design to evaluate the efficacy and safety of Q702 in subjects diagnosed with relapsed or refractory chronic graft-versus-host disease. The research methodology involves a sequence of study visits beginning with a screening visit to determine eligibility. Subsequent follow-up visits are conducted to monitor clinical progression and safety parameters, concluding with an end-of-study visit. The total duration of the study is estimated to span from January 2026 to April 2029. Early termination from the study may occur based on predefined clinical conditions or safety protocols.

The efficacy assessment for this phase 2 clinical trial involves evaluating the clinical response in patients with chronic graft-versus-host disease. Specific parameters for measuring efficacy and the methods for data collection are not specified in the provided documentation.